Bright Minds Biosciences is a biotechnology company developing selective serotonin receptor agonists to treat neurological and psychiatric disorders including epilepsy, depression, and other central nervous system conditions. The company's proprietary platform uses patented highly selective compounds targeting specific serotonin receptor subtypes, designed to maximize therapeutic efficacy while minimizing adverse effects associated with existing serotonergic therapies. Its lead program, BMB-101, is a 5-HT2C selective agonist being developed as an anti-epileptic treatment, with secondary candidates in development for neuropsychiatric and pain-related indications, supported by exclusive patent licenses covering broad molecular families across major markets.